Lenvatinib Olpha (Lenvatinib)

Lenvatinib acts on key signaling pathways involved in tumor growth and angiogenesis, making it useful in several solid‑tumor indications.

• Differentiated thyroid carcinoma: improves progression‑free survival in patients with radioactive‑iodine refractory disease.
• Renal cell carcinoma: reduces tumor growth and extends survival in advanced clear‑cell RCC.
• Hepatocellular carcinoma: prolongs overall survival in patients with unresectable disease.

• Lenvatinib inhibits multiple receptor tyrosine kinases, including VEGFR 1‑3, FGFR 1‑4, PDGFRα, RET and KIT. By blocking these pathways, it suppresses tumor angiogenesis, reduces endothelial cell proliferation, and interferes with oncogenic signaling that drives cancer cell growth and survival. The drug’s binding to the ATP‑binding pocket of these kinases prevents downstream phosphorylation cascades, leading to decreased MAPK and PI3K/AKT pathway activity, which further limits tumor cell proliferation and survival.

Lenvatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hypertension: elevated blood pressure often requiring antihypertensive therapy.
• Diarrhea: frequent loose stools that may lead to dehydration.
• Fatigue: persistent tiredness affecting daily activities.
• Nausea: feeling of sickness that may be mild to moderate.
• Decreased appetite: reduced desire to eat, potentially causing weight loss.
• Proteinuria: presence of protein in urine detectable on testing.

Serious or Rare Side Effects

• Severe hemorrhage: life‑threatening bleeding events.
• Hepatic failure: significant liver enzyme elevation or liver dysfunction.
• Arterial thromboembolism: clot formation in arteries causing ischemia.
• Gastrointestinal perforation: hole formation in the stomach or intestines.
• Fistula formation: abnormal connections between organs.
• Severe hypertension: blood pressure crisis requiring urgent care.

Before initiating Lenvatinib therapy, clinicians should consider several precautionary measures to minimize risks.

• Monitor blood pressure: check regularly and manage hypertension promptly.
• Assess liver function: perform baseline and periodic liver enzyme tests.
• Evaluate for proteinuria: conduct urine analysis before and during treatment.
• Review concomitant medications: avoid strong CYP3A4 inhibitors and adjust doses of anticoagulants.
• Educate patients on signs of serious adverse events: report bleeding, severe abdominal pain, or sudden weight loss.
• Store at room temperature: keep in the original container, protect from moisture and light.

Lenvatinib can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Lenvatinib exposure and toxicity.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened risk of bleeding.
• High‑dose aspirin or NSAIDs: increased bleeding potential.
• Strong inducers of CYP3A4 (e.g., rifampicin): may reduce drug levels and effectiveness.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., erythromycin): may modestly raise Lenvatinib concentrations.
• Antihypertensive agents: Lenvatinib may elevate blood pressure, requiring dose adjustments.
• Diuretics: potential for electrolyte disturbances.
• Hormonal contraceptives: possible reduced efficacy, advise alternative contraception.